ImmunityBio/IBRX

$5.27

8.35%
-
1D1W1MYTD1YMAX

About ImmunityBio

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

Ticker

IBRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Patrick Soon-Shiong

Employees

628

Headquarters

San diego, United States

ImmunityBio Metrics

BasicAdvanced
$3.53B
Market cap
-
P/E ratio
-$1.13
EPS
1.17
Beta
-
Dividend rate
$3.53B
1.17199
$6.93
$1.25
4.17M
5.046
-2.08%
-134.71%
-377.77%
5,677.669
159.17%
-8.22%
0.93%

What the Analysts think about ImmunityBio

Analyst Ratings

Majority rating from 1 analysts.
Hold

Price Targets

Average projection from 2 analysts.
5.12% downside
High $5.00
Low $5.00
$5.27
Current price
$5.00
Average price target

ImmunityBio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-233,300% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$100K
∞%
Net income
$-233.3M
144.29%
Profit margin
-233,300%
-∞%

ImmunityBio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 94.44%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.32
-$0.19
-$0.35
-
Expected
-$0.24
-$0.26
-$0.18
-$0.16
Surprise
36.17%
-25.49%
94.44%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for ImmunityBio stock?

ImmunityBio (IBRX) has a market cap of $3.31B as of April 21, 2024.

What is the P/E ratio for ImmunityBio stock?

The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of April 21, 2024.

Does ImmunityBio stock pay dividends?

No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next ImmunityBio dividend payment date?

ImmunityBio (IBRX) stock does not pay dividends to its shareholders.

What is the beta indicator for ImmunityBio?

ImmunityBio (IBRX) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the ImmunityBio stock price target?

The target price for ImmunityBio (IBRX) stock is $5, which is 5.12% below the current price of $5.27. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ImmunityBio stock

Buy or sell ImmunityBio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing